FORT WORTH, Texas, March 15 (OTC Bulletin Board: WNDM) Wound Management Technologies, Inc., a growing provider of specialty medical products, announced today that its subsidiary Wound Care Innovations will exhibit at the DFCon 10 Global Diabetic Foot Conference in Los Angeles March 18-20. Expected attendance is more than 1000 physicians, clinicians, researchers, scientists, and limb salvage experts from all 50 U.S. states and more than 42 foreign countries. An evidence based study using their advanced wound care collagen product, CellerateRx®, "Activated Collagen Accelerates Wound Repair and Modulates Cytokine Production in Whole Blood and PBMC Cultures" by Greg Pott, PhD, K.Scott Beard, PhD, Matthew Regulski, DPM, and Leland Shapiro, MD is one of the accepted abstracts presented at the conference.
Advertisement
"We are delighted to once again participate in this important conference," states Cathy Bradshaw, President of Wound Care Innovations. "Diabetic wounds continue to be one of the most serious issues we face in health care today. Diabetes affects 24 million people in the U.S. and 189 million people worldwide and up to 25% of those will develop a foot ulcer. We are excited about the outcomes we have seen with CellerateRx® in addressing these difficult wounds, and about the important clinical data presentation this year."
Advertisement
CellerateRx® patented advanced wound care collagen products are FDA cleared for all acute and chronic wounds except 3rd degree burns.
For Wound Management Technologies Shareholder Information please call 561-515-6035 or go to http://www.wmgtech.com
About Wound Care Innovations, LLC
Wound Care Innovations, LLC (WCI) is a wholly owned subsidiary of Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida. WCI markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on CellerateRx, please visit the WCI website at www.Celleraterx.com .
About Wound Management Technologies, Inc.
Wound Management Technologies Inc's primary focus is the distribution of its unique, patented collagen product, CellerateRX®, in the $3.2B worldwide advanced wound care market, a market that is growing due to aging populations and the increase of diabetes. Over the past 2 years WMT has focused on developing evidenced-based studies on CellerateRX and gaining physician awareness by participation in key industry conferences. Now WMT is focused on expanding sales through partnerships and contracted independent representatives. WMT has other advanced biotech products in development for bone wax, bone void fillers and shingles pain reduction as well as a subsidiary focused on eHealth technology for secure healthcare data collaboration and storage. More information can be found on the company's websites: www.wmgtech.com, www.CellerateRX.com , and www.SecureeHealth.com .
Safe Harbor Statement:
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
For Further Information:
Shareholder Relations-Communications 561-515-6035
SOURCE Wound Management Technologies, Inc.
